Singapore, Jan. 21 -- Duke-NUS Medical School in Singapore has noted theannouncement by Boehringer Ingelheimof a Phase IIa clinical study evaluating BI 765423, a first-in-class IL-11 inhibitor for idiopathic pulmonary fibrosis (IPF). The programme is among prominent fewpreclinical discoveries from Singapore to progress into Phase II clinical evaluation, marking a significant translational milestone with the potential to impact a devastating disease with limited treatment options.

The programme emerged from adeep academic medicine collaboration between Duke-NUS and SingHealth, including the National Heart Centre Singapore (NHCS). The work was led by Duke-NUS scientists, including Professor Stuart A Cook and Dr Sebastian Schafer, whose res...